New Peptide Analog Burns Fat Continuously Without Reducing Appetite
Prolactin-releasing peptide analog promotes sustained fat burning for weight loss, offering new approach beyond appetite suppression.
20 articles
Prolactin-releasing peptide analog promotes sustained fat burning for weight loss, offering new approach beyond appetite suppression.
Deep dive into uncoupling protein 1 mechanisms, sympathetic nervous system control, and therapeutic strategies for metabolic health and longevity.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
A steroid hormone activates receptor GPR56 to block ferroptosis, a form of iron-driven cell death linked to liver disease.
New research reveals how the cholesterol medication bempedoic acid directly activates PPARΞ±, boosting fat metabolism beyond its known effects.
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
Knocking out BNIP3 in macrophages reduced adipose inflammation and improved insulin sensitivity in obese mice, revealing a new therapeutic target.
Deep dive into GLP-1 receptor mechanisms, cAMP-PKA signaling cascades, and their role in metabolic health and longevity pathways.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
Scientists discover how a hypothalamic calcium channel detects leucine from dietary protein to trigger satiety and drive weight loss.
Research reveals how the steroid hormone pregnenolone allows cancer cells to evade immune detection and reduces immunotherapy effectiveness.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
Discover how this powerful gut hormone controls hunger, blood sugar, and may hold keys to healthy aging.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
Breakthrough study reveals sepiapterin dramatically outperforms existing PKU therapy, offering hope for better metabolic control.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
Go beyond the basics and explore how GLP-1 coordinates insulin release, appetite suppression, and cellular protection β and why these mechanisms matter for long-term metabolic health.
Scientists discover signaling pathways that could enhance insulin-producing cells and improve diabetes treatment outcomes.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.